Bajaj Healthcare Ltd (BAJAJHCARE) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Bajaj Healthcare Ltd on NSE and BSE, with an AI summary of each filing.
Transcript of Earnings Call for Q2H1FY27
Transcript · 27 Oct 2026, 9:48 pm
Intimation for Audio Recording of Earnings Call for Q2FY27
Audio / Video · 20 Oct 2026, 12:48 am
Bajaj Healthcare Releases Q2 & H1 FY27 Earnings Call Audio Recording Bajaj Healthcare Limited has made available the audio recording of its earnings conference call held on 19th Oct'26. The call reviewed the company's financial performance for the quarter and half-year ended 30th Sep'26 (Q2 & H1 FY27). The recording has been uploaded to the company's official website in compliance with Regulation 30 of the SEBI (LODR) Regulations, 2015.
Press Release on the financial results of the Company for the quarter ended September 30, 2026
Press Release · 18 Oct 2026, 3:58 am
Bajaj Healthcare Reports Strong Q2 FY27 Earnings Driven by Formulations Growth Bajaj Healthcare posted an 18.9% YoY increase in Q2 FY27 revenue from operations to Rs. 175.9 Crore, with EBITDA rising 12.2% YoY to Rs. 32.1 Crore and PAT growing 26.9% YoY to Rs. 14.1 Crore. Formulations surged 82.0% YoY to Rs. 41.7 Crore, while API exports expanded 28.5% YoY to Rs. 62.6 Crore. The company secured first-in-India DCGI approval and commenced commercial rollout for Cenobamate Tablets in Sep'26. Additionally, India Ratings upgraded its long-term rating to IND A/Stable.
Statement of Deviation & Variation for the quarter ended September 30, 2026
Others (Uncategorized) · 17 Oct 2026, 11:27 pm
Bajaj Healthcare Reports Nil Deviation in Preferential Issue Proceeds Utilization Bajaj Healthcare confirmed nil deviation or variation in the utilization of funds raised via equity shares allotted on conversion of warrants for the quarter ended 30th Sep'26. Against a modified total allocation of ₹20,497.00 Lakhs, the company has deployed ₹19,905.96 Lakhs. Key deployments include ₹15,000.00 Lakhs fully utilized toward secured/unsecured loan repayments, ₹2,912.48 Lakhs utilized out of ₹3,500.00 Lakhs allocated for capital expenditure, and ₹1,993.48 Lakhs utilized for general corporate purposes. CARE Ratings continues as the monitoring agency.
Monitoring Agency Report for the quarter ended September 30, 2026
Others (Uncategorized) · 17 Oct 2026, 11:20 pm
Bajaj Healthcare Preferential Issue Monitoring Report For Q2FY27 CARE Ratings confirmed no deviation in Bajaj Healthcare’s utilization of Rs. 204.97 crore raised via preferential issue and warrants for the quarter ended 30th Sep'26. Total cumulative deployment reached Rs. 199.06 crore, comprising Rs. 150.00 crore for loan repayments, Rs. 29.13 crore for capex, and Rs. 19.93 crore for general corporate purposes. Capex spending during Q2FY27 stood at Rs. 6.26 crore, partially offset by a Rs. 0.45 crore property advance refund. Unutilized proceeds of Rs. 5.91 crore remain parked in the designated monitoring bank account.
Financial Results for the quarter ended September 30, 2026
Financial Result · 17 Oct 2026, 11:10 pm
Bajaj Healthcare Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Outcome · 17 Oct 2026, 10:47 pm
Outcome of the Board Meeting held on 17th October 2026
Outcome · 17 Oct 2026, 10:44 pm
Bajaj Healthcare Ltd - Financial Result for the Quarter ended 30th Sep'26 (Standalone, INR Lakh) ■ Revenue: 17,590 (+18.9% YoY | +6.2% QoQ) ■ EBITDA: 3,121 (+15.8% YoY | +8.5% QoQ) ■ EBITDA Margin (%): 17.7 (-48 bps YoY | +38 bps QoQ) ■ PAT: 1,409 (+26.9% YoY | +2.9% QoQ) ■ EPS (INR): 4.18 (+20.5% YoY | +3.0% QoQ)
Receipt of Hon''ble NCLT Order approving acquisition of Genrx Pharmaceuticals Private Limited on a going concern basis
Others (Uncategorized) · 14 Oct 2026, 9:52 pm
NCLT Approves Bajaj Healthcare’s Acquisition of Genrx Pharmaceuticals The Hon’ble NCLT, Mumbai Bench, approved Bajaj Healthcare Limited's acquisition of Genrx Pharmaceuticals Private Limited (in Liquidation) on a going concern basis via an order dated 13th Oct'26. The approval follows the company's prior disclosures in Apr'25. Post-implementation of the terms specified in the NCLT order, Genrx Pharmaceuticals will become a wholly owned subsidiary of Bajaj Healthcare. The order became effective immediately on 13th Oct'26, and the company will initiate necessary actions to execute the acquisition in compliance with the NCLT directive.
Earning Call Invite
Intimation · 19 Oct 2026, 5:00 pm
Bajaj Healthcare Schedules Q2 and H1 FY27 Earnings Call on 19th Oct'26 Bajaj Healthcare Limited has scheduled its earnings conference call on 19th Oct'26 at 5:00 PM IST to discuss financial results for Q2 and H1 ended 30th Sep'26. The management team will be represented by Managing Director Anil Jain and Chief Financial Officer Rohan Parekh. Universal dial-in access is available via +91 22 6280 1550 and +91 22 7115 8378, alongside international toll-free options for the US, UK, Singapore, and Hong Kong.
Disclosure under Regulation 30 of the SEBI (LODR) Regulations, 2015 for the sale of a business unit of the Company
Others (Uncategorized) · 12 Oct 2026, 11:54 pm
Bajaj Healthcare Sells Dahej Undertaking for ₹14.67 Crore Bajaj Healthcare has executed a Deed of Assignment on 12th Oct'26 to sell its Dahej Industrial Area undertaking in Bharuch, Gujarat, to Spa Vet Private Limited and Indosol Pure Technologies Private Limited for approximately ₹14.67 crore. The undertaking was non-operational during the previous financial year, contributing nil to turnover and revenue. The transaction is non-related party, executed outside a scheme of arrangement, and had previously secured shareholder approval on 5th Aug'23 in compliance with Regulation 37A of SEBI LODR Regulations.
BAJAJ HEALTHCARE LIMITED has informed the Exchange about Board Meeting to be held on 17-Oct-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 .
Intimation · 17 Oct 2026, 5:30 am
To consider and approve the un-audited financial results for the quarter and half year ended September 30, 2026
Intimation · 17 Oct 2026, 5:30 am
Bajaj Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 17/10/2026 ,inter alia, to consider and approve the un-audited financial results ....
Intimation · 17 Oct 2026, 5:30 am
Bajaj Healthcare Schedules Board Meeting for Q2 and H1 FY27 Results Bajaj Healthcare Limited has scheduled its Board of Directors meeting on 17th Oct'26 to consider and approve the un-audited financial results for the quarter and half-year ended 30th Sep'26. In compliance with SEBI Insider Trading Regulations, the company's trading window for designated persons and their immediate relatives has been closed effective 1st Oct'26 and will remain closed until 48 hours post the declaration of the financial results.
Submission of Voting Results and Scrutinizer''s Report
Annual General Meeting · 22 Sept 2026, 10:48 pm
Bajaj Healthcare Approves All Resolutions at 33rd AGM Including Rs 1.50 Dividend Bajaj Healthcare Limited announced the approval of all six resolutions at its 33rd AGM held on 21st Sep'26 with requisite majorities. Key approvals include the adoption of FY26 audited financial statements, payment of a final dividend of Rs. 1.50 per equity share, and the reappointment of director Mr. Pakshal Anil Jain. Shareholders also passed special resolutions approving the continuation of directorship for Mr. Gopalakrishnan Kesavan beyond age 75 and the FY27 remuneration for Non-Executive Non-Independent Director Mr. Sandeep Shah alongside cost auditor remuneration ratification.
Proceedings of the 33rd Annual General Meeting of the Company held on September 21, 2026
Annual General Meeting · 21 Sept 2026, 11:03 pm
Intimation of Record Date for the payment of Final Dividend for the financial year 2025-26
Dividend · 03 Sept 2026, 5:06 pm
Intimation for Inland Letters sent to Shareholders
Annual General Meeting · 29 Aug 2026, 9:56 pm
Bajaj Healthcare Schedules 33rd AGM for Sep 21st, 2026 Bajaj Healthcare has scheduled its 33rd Annual General Meeting (AGM) for Mon, 21st Sep'26, at 3:00 PM IST via video conferencing. The company has dispatched letters with the web link for its FY25-26 Annual Report to shareholders who have not registered an email address as of the cut-off date of 21st Aug'26. This action complies with SEBI regulations. The company also reminded shareholders holding physical shares to update their KYC details and consider dematerialization to ensure receipt of future payments and communications.
Intimation for Business Responsibility and Sustainability Report for the financial year 2025-26
Others (Uncategorized) · 29 Aug 2026, 9:35 pm
Bajaj Healthcare Files FY26 Business Responsibility and Sustainability Report Bajaj Healthcare Limited filed its Business Responsibility and Sustainability Report for FY26 on 29 Aug'26. Pharmaceutical products accounted for 100% of turnover. Export sales contributed approximately 31% of total turnover, serving over 62 countries. Total employee turnover rate surged to 33.39% in FY26 from 3.9% in FY25, driven by a sharp rise in the male employee turnover rate to 32.37%. Accounts payable days decreased to 106 in FY26 from 121 in FY25. The company reported zero CSR complaints and zero product recalls.
Intimation of the Annual Report for the financial year 2025-26
Others (Uncategorized) · 29 Aug 2026, 9:24 pm
Intimation of 33rd Annual General Meeting and dispatch of Annual Report of the Company for the financial year 2025-26
Annual General Meeting · 29 Aug 2026, 9:03 pm
Intimation of allotment of equity shares pursuant to exercise of ESOPs
Others (Uncategorized) · 21 Aug 2026, 11:29 pm
Bajaj Healthcare Allots Equity Shares Under Employee Stock Option Scheme Bajaj Healthcare allotted 2,500 equity shares on Aug 21, '26, under its ESOP Scheme 2024. The shares, with a face value of ₹5, were issued upon exercise of vested options at an exercise price of ₹5 per share. This allotment increased the paid-up equity share capital from ₹16,83,13,305 to ₹16,83,25,805. The total number of issued equity shares now stands at 3,36,65,161. The new shares will rank pari-passu with existing equity. The diluted EPS for the quarter ended Jun 30, '26 was ₹4.06.
The Company has received the approval from DCGI to manufacture and market Cenobamate API and Tablets
Others (Uncategorized) · 12 Aug 2026, 10:12 pm
Bajaj Healthcare Receives DCGI Nod for Epilepsy Drug Cenobamate Bajaj Healthcare has received approval from the DCGI on 12 Aug '26 to manufacture and market Cenobamate API and Tablets. This makes it the first company to launch the next-generation antiseizure medication in India. The approval covers six strengths ranging from 12.5 mg to 200 mg. Cenobamate is used for partial-onset seizures in adults. The launch marks a significant entry into advanced therapies, strengthening the company's Central Nervous System (CNS) product portfolio and positioning it for long-term growth in the Indian pharmaceutical market.
Revision in Credit Rating
Others (Uncategorized) · 07 Aug 2026, 12:33 am
Bajaj Healthcare Credit Rating Upgraded by India Ratings on Improved Profile India Ratings and Research (Ind-Ra) upgraded Bajaj Healthcare's credit ratings on 06 Aug'26, citing a strengthened business profile. The long-term bank loan facilities were upgraded to 'IND A/Stable' from 'IND A-/Stable', and short-term facilities to 'IND A1' from 'IND A2+'. This reflects improved FY26 financial performance, with EBITDA margins rising to 17.2% and net leverage improving to 2.1x from 2.9x. The upgrade is supported by healthy order visibility, a strategic shift to regulated markets, and growing CDMO engagements.
Transcript of Earnings Call for Q1FY27
Transcript · 27 Jul 2026, 9:27 pm